OS Therapies shares rise 10.19% intraday after FDA upgrades OST-HER2 meeting to Type B pre-BLA, signaling accelerated approval path.

OS Therapies surged 10.19% intraday, driven by the FDA upgrading the OST-HER2 meeting type from Type D to Type B pre-BLA in March 2026, signaling a shift toward accelerated approval. The company plans to submit clinical data by late Q1 2026 and aims for accelerated approval in the second half of 2026. OS Therapies, a global leader in Listeria-based cancer immunotherapy, also raised $2 million via convertible notes and warrants on March 4, 2026, to fund clinical development and operations. Its core product, OST-HER2, holds FDA orphan drug, fast track, and rare pediatric disease designations, with a February 2026 priority review voucher valued at $205 million.